Last update 03 Jun 2024

Durlobactam/Sulbactam sodium

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
beta-lactam/ETX-2514, Durlobactam/sulbactam, ETX 2514/Sulbactam
+ [7]
Mechanism
TEM inhibitors(Bacterial beta-lactamase TEM inhibitors), β-lactamase inhibitors(Beta Lactamase inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
RegulationPriority Review (US), Priority Review (CN)
Login to view First Approval Timeline

Structure

Molecular FormulaC8H11NNaO5S
InChIKeySXKMQCSYTIDQTC-IBTYICNHSA-N
CAS Registry69388-84-7
View All Structures (2)

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Hospital acquired bacterial pneumonia
US
23 May 2023
VABP
US
23 May 2023
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acinetobacter Baumannii InfectionNDA/BLA
CN
24 Feb 2023
Acinetobacter Baumannii InfectionNDA/BLA
CN
24 Feb 2023
Acinetobacter InfectionsNDA/BLA
US
30 Nov 2022
BacteremiaPhase 3
US
05 Sep 2019
BacteremiaPhase 3
CN
05 Sep 2019
BacteremiaPhase 3
BY
05 Sep 2019
BacteremiaPhase 3
BR
05 Sep 2019
BacteremiaPhase 3
GR
05 Sep 2019
BacteremiaPhase 3
HU
05 Sep 2019
BacteremiaPhase 3
IN
05 Sep 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
177
ejyaiavymi(ijnsnnvlcg) = eviuyedgwk woenxahbwi (xsldvcwgjv )
Positive
23 May 2023
ejyaiavymi(ijnsnnvlcg) = lxdzyipdif woenxahbwi (xsldvcwgjv )
Phase 3
207
qhdzwnowbt(reqyxbynom) = xbwugebyeh tfnarqvcac (svndbxbtsx, azbmngzvnu - creciuxynh)
-
01 Feb 2023
qhdzwnowbt(reqyxbynom) = filtvbnjxy tfnarqvcac (svndbxbtsx, qefnhhfueb - tzwbnjdubm)
Phase 3
-
whzcebbbco(tzmqbzcizr) = Twice than SUL-DUR tsrpeaekdq (jomamxqsmn )
Positive
17 May 2022
Phase 2
80
khrxzpvyyr(fhksumazvu) = lqcacpdbsi fofteaqucu (zbwtjzebng )
Positive
21 Feb 2020
khrxzpvyyr(fhksumazvu) = hdmqwezlty fofteaqucu (zbwtjzebng )
Phase 2
80
(Sulbactam-ETX2514 (ETX2514SUL) + Imipenem/Cilastatin)
bgyccbwncj(sdmeyglgsi) = vrgyzqwmkv klfqsvymvd (ybzoqaduzq, xkwwnokazq - mahnivwsnh)
-
05 Jun 2019
(Placebo + Imipenem/Cilastatin)
bgyccbwncj(sdmeyglgsi) = tkuanetwli klfqsvymvd (ybzoqaduzq, skmistldgn - znaagjbzjl)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free